We examined the distribution of endothelin-1-like immunoreactivity in human placenta, using the immunoperoxidase technique. A specific polyclonal antibody to endothelin-1 was raised in rabbits, which mgnized endothelin-1 and its precursor molecule, big endothelin. Immunoperoxidase staining revealed that endothelin-1-like immunoreactivity was widely distributed in the placenta. Endothelin-l-like immunoreactivity was present in endothelial cells of capillaries of the microvilli and in small-and medium-sized arteries and veins. The distribution of endothelin-1-like immunoreactivity was similar to the distribution of Factor VIII-related antigen, which stains endothelial cells. The nature of endothelin in the human placenta was further examined with cultured umbilical vein endothelial cells. Endothelial cells released endothelin-like material into the Literature Cited
Introduction
The human fetoplacental circulation is believed to be maximally d i l a t e d in normal pregnancy (11) . Fetoplacental blood flow, however, is reduced in states of hypoxia, fetal disuess, intrauterine growth retardation, or maternal hypertension (20.2 3) . The etiology of fetoplacental vasoconstriction is not known, but stimulation of local autacoids may contribute to the pathogenesis of these disorders. Endothelin-1, a 21 amino-acid peptide first isolated from porcine aortic endothelium, is a potent vasoconstrictor which has been shown to play an important role in the control of vascular tone in many vascular beds (6, 21, 28) . Unlike other vasoactive substances, endothelin has a prolonged time-action profile, making it a prime candidate for mediating sustained vasoconstriction. Endothelin levels have been reported to be elevated in the maternal blood of hypertensive pregnancies compared with normal pregnancy, an observation culture medium. The amount of endothelin-like material varied directly with time of incubation and the amount of fetal calfserum in the culture medium. Fractionation of the endothelin-1-like material by reversed-phase high-performance liquid chromatography (HPLC) and quantitation by radioimmunoassay (RIA) revealed that endothelin-like immunoreactivity co-eluted with endothelin-1 but not with big endothelid. We conclude that endothelin-1-like immunoreactivity is widely distributed in vascular endothelium of the human placenta. These data are compatible With a role for endothelin as an autocrine or paracrine modulator of vascular tone in the human placenta. (J Histodiem Cytochem 41:535-541, 1993) KEY WORDS: Endothelin; Placenta; Human; Immunohistochemistry; HPLC; RIA. that has led to the hypothesis that increased endothelin levels may also contribute to vasoconstriction in the fetoplacental circulation in complicated pregnancies (10, 12, 19) . It is uncertain whether endothelin can function as a circulating hormone, because it is removed from the circulation by a single pass through the lungs, and when introduced into the heart in small amounts endothelin causes coronary constriction, arrhythmias, and death ( 5 ) . Although most investigators now believe that endothelin is an autacoid acting close to its site of production, a highly potent peptide such as endothelin may have significant effects in a single pass through the circulation.
To fulfill the requirements of a tissue-active hormone system, local production of endothelin must be demonstrated, specific endothelin receptors defined, and biological actions of endothelin determined in its target cells. Several of these criteria have already been met in the human placenta. Endothelin causes prolonged vasoconstriction in the perfused human fetoplacental cotyledon which is mediated by binding of endothelin to specific high-affinity receptor sites (4, 16, 25) . However, for endothelin to have important local functions in regulation of fetoplacental vascular resistance in vivo, endothelin must also be produced locally. This hypothesis is supported by the demonstration that genes for endothelin are expressed by the placenta (14) and by cultured human umbilical vein en-dothelial cells (28) . However, the cell type or types that make endothelin in the placenta have not been defined. Endothelin production may not be limited to endothelial cells, since endothelin-1 gene expression has been shown in many other types of cells, including breast epithelium (I), avascular human amnion (2), and pituitary (29) . Endothelin production has also been reported in endometrium (15) and has been identified by immunohistochemistry in vascular smooth muscle cells in patients with atherosclerosis (9) and in bronchial epithelium (17) .
These observations prompted us to investigate the site(s) of distribution of endothelin in the human placenta. A high-titer specific antibody was generated to endothelin-1 and was used to localize endothelin-1-like immunoreactivity in placenta by the immunoperoxidase technique. The chemical nature of the endothelin-1-like immunoreactivity was further evaluated by studying the isoform of endothelin produced by cultured human umbilical endothelial cells.
Materials and Methods

Materials
Endothelin-1 [endothelin[ 
Tissue Localization of Endotbelin-lihe Immunoreactivity
Placentas were obtained from term pregnant women with uncomplicated pregnancies. All of the protocols in this manuscript have been approved by the Research, Clinical Investigations and Publications Committee of North Shore University Hospital. Some of the patients underwent cesarean sections for prolonged labor or other obstetrical indications, but none were hypertensive, diabetic, or pre-eclamptic, and none received general anesthesia. Placentas were brought to the laboratory, cut into 5-mm cubes, and immersion-fixed in 4% paraformaldehyde (in 50 mM phosphate buffer, pH 7.2,25"C) within 3 min of delivery. Fixation was continued at 4% overnight. The tissue was dehydrated in alcohols and embedded in paraffin. Sections (5 pm) were mounted on poly-L-lysine-coated slides.
Immunoperoxidase staining was performed by the ABC method as previously described (26) . In brief, the sections were dewaxed in xylene, washed in absolute ethanol for 5 min. and quenched in methanol containing 3% H202 at 25°C for 30 min. The sections were washed for 5 min in tapwater, followed by a 30-min incubation in trypsin (0.1% trypsin in 0.1% CaC12, wlv) to activate antigenic sites. After washing in tapwater, the sections were incubated overnight at 4'C with specific endothelin antiserum diluted 1:100-1:1500 in PBS containing 3% normal goat serum. The endothelin antiserum used for the immunoperoxidase studies was the same as that used for the radioimmunoassay (see below). After washing in PBS, the sections were incubated at 25'C for 30 min with biotinylated goat anti-rabbit IgG (Vectastain Elite Kit) (Vector Laboratories; Burlingame, CA) diluted 1:lOO with PBS (containing 3% normal goat serum) and, after further washing, with avidin-biotin-peroxidase complex diluted 1:lOO in PBS for 30 min. The sites of peroxidase activity were visualized by incubation in a solution containing 0.05 % 3,3'-diaminobenzidine (Kirkegaard & Perry; Gaithersburg, MD) in 0.01% H202 for 5 min. Sections were counterstained with Mayer's hematoxylin (Sigma; St Louis, MO) for 2 min, washed, and coverslipped.
In each experiment, an additional section was stained with anti-Factor VIII-related antigen (1:lOOO) (Dako; Carpinteria, CA), which served as a positive control and permitted a comparison between the distribution of endothelin-1 and that of the endothelial cell marker, Factor VIII-related antigen. Negative controls included the use of specific antiserum absorbed with endothelin-positive cells (cultured human umbilical endothelial cells, 1 x lo6 cells/l ml of diluted antiserum at 25'C for 18 hr) or non-immune serum instead of the primary antiserum, or omission of one of the steps in the avidin-biotin-complex procedure. Each experiment was repeated at least three times.
Endothelial Cell Culture. Primary cultures of umbilical vein endothelial cells were obtained by standard methods (8) . In brief, umbilical cords were processed within 2 hr of delivery. The umbilical vein was flushed with 30 ml of PBS to remove blood. The cord was blotted and the vein was filled with 0.1% collagenase-1 in PBS (Worthington Biochemical; Freehold, NJ). the ends tied, and immersed in PBS for 20-30 min at 37'C. The digestion was terminated by flushing the vein with tissue culture medium consisting of Medium 199 with 20% fetal calf serum, penicillin (100 U/ml), streptomycin (10 wglml), endothelial cell-growth factor (75 pg/ml), and heparin (7.5 U/ml). After low-speed centrifugation (664 x g for 5 min) the supernatant was aspirated and the pellet was re-suspended and placed in T25 cm2 Primaria flasks (Becton Dickinson; Rutherford, NJ) with 6 ml of the same medium. After 24 hr the medium was replaced. The medium was changed twice a week. Confluence occurred at 1-2 weeks and cells were studied at passages 2-4. Cells were identified as endothelial cells by their typical cobblestone appearance and positive immunostaining for Factor VIIIrelated antigen, with negative immunostaining for smooth muscle antigen and desmin.
The time course for appearance of immunoreactive endothelin-1 in the medium was studied using cells grown to confluence in T75 flasks containing 20 ml of tissue culture medium. At 1, 3, 6, 10, 24, and 48 hr, 2-ml aliquots of media were removed, lyophilized, and frozen for the determination of immunoreactive endothelin-1. Additional experiments were performed to determine the effect of various concentrations of fetal calf serum (0, 5 , 10, and 20%) on the production of immunoreactive endothelin-1 at 6 hr. To further define the nature of the immunoreactive material produced by endothelial cells, additional cells were incubated for 24 hr in the absence of fetal calf serum and the medium frozen (-2O'C) until analysis. In these experiments the medium was fractionated by HPLC before radioimmunoassay (see below).
Endothelin Radioimmunmsay. Endothelin levels in medium were measured by specific RIA with an antibody raised against synthetic endothelin-l conjugated to bovine thyroglobulin. The molar crossreactivity of the antibody at 50% BIBo is 100% for endothelin-1, 88% for big human endothelin[l-38], 97% for big porcine endothelin[l-39], <1% for endothelin-2 and endothelin-3, and <0.2% for sarafotoxin, angiotensin 11, bradykinin, and auriculin (26) . Samples of medium were immediately frozen and lyophilized. Samples were dissolved in assay buffer (0.1 M sodium phosphate, 0.05 M NaCI, 0.1% BSA, 0.05 M EDTA, 0.01% sodium azide, 0.1% Triton X-100, pH 7.4) for direct RIA. In brief, 0.1 ml of sample or endothelin-1 standard in assay buffer and 0.1 ml of antibody (final dilution 1:180,000, BolT = 40%) were pre-incubated at 4'C for 24 hr, followed by the addition of 0.1 ml of ('251]-endothelin-l containing approximately 5000 cpm and further incubated for 24 hr. Separation of the bound from the free ligand was accomplished by the double antibody method. Goat anti-rabbit antiserum (25 NI) (Pel Freeze Biologicals; Rogers, AR) and 1% normal rabbit serum (1 ml diluted in PBS) were added and the tubes placed on ice for 30 min before the addition of polyethylene glycol (400 ~1 of 4% PEG, MW 8000, in water). Tubes were centrifuged for 15 min at 3000 rpm, the supernatant was aspirated, and the pellets counted for lZ5I. The sensitiv- Figure 1 . Endothelin-1-like immunostaining in the human placenta. This photomicrograph demonstrates endothelin-1-like immunostaining along the endothelial surfaces of capillaries in placental villi (arrows). lmmunostaining was limited to the endothelial surfaces and was not present in syncytiotrophoblast or cytotrophoblast cells. Original magnification x 625. Bar = 60 vm. ity of the ET-1 radioimmunoassay was 0.6 pg, and the ED50 was 9.8 pgltube. All samples from individual experiments were measured in a single assay.
High-performance Liquid Chromatography Separation of Endothefins. Reversed-phase HPLC was used to separate endothelins. In brief, lyophilized samples were dissolved in 100 pI deionized water. Separation of endothelins was achieved using a 3.9 mm x 15 cm Nova-Pak C18 column (Waters; Milford. MA) connected to a Perkin-Elmer (Norwalk, CT) Series 4 pump system with a Rheodyne 7125 manual injection valve (Rheodyne; Cotali. CA). Samples were injected in a volume of 150 PI. Elution was achieved using a linear gradient from 80% Buffer A (25 mM sodium phosphate buffer, 5 % acetonitrile. pH 6.0) and 20% Buffer B (95% acetonitrile) to 65% Buffer A over 20 min at a flow rate of 1.0 mllmin. Fractions (30 sec) were collected in 12 x 75-mm polystyrene test tubes. The acetonitrile was evaporated at room temperature and the remainder of the sample was lyophilized. The positions of endothelin peaks were determined by injection of approximately 100 pg of endothelin-1 and big human endothelin-1[1-381. Recovery of endothelin-1 standard was 40 f 5 % (n = 4).
Results
The distribution of endothelin-1-like immunoreactivity was examined in term human placentas. Fine granular immunostaining was localized to endothelial cells lining the capillaries of placental microvilli (Figure 1 ). Endothelin-1-like immunostaining was present in virtually all of the capillary endothelium. The staining was specific for endothelin, since immunostaining was diminished or absent when human umbilical vein endothelial cells were used to absorb the primary antiserum (Figure 2 ) . When primary antiserum was substituted by non-immune serum or when one of the steps in the avidin-biotin complex procedure was omitted, there was no immunostaining. In addition to endothelin-1-like immunostaining in the endothelial cells lining capillaries, there was fo-cal immunostaining in endothelial cells lining small to medium sized blood vessels ( Figure 3A) . Endothelin-1-like immunostaining was similar in distribution to the immunostaining of the endothelial cell marker, Factor VIII-related antigen ( Figure 3B ). Syn-cytiotrophoblast~, cytotrophoblasts. connective tissue, and vascular smooth muscle cells were consistently negative for endothelin-llike immunostaining.
To further characterize the nature of the endothelin-1-like material, additional studies were performed in cultured endothelial cells obtained from the umbilical vein. Endothelin-1-like immunoreactivity was present in the medium and increased with increasing incubation times up to 48 hr ( Figure 4 ) and with increasing concentrations of fetal calf serum in the medium (Figure 5 ) . Unconditioned medium containing fetal calf serum (20%) consistently registered values less than 1 pg/100 p1 on the endothelin-1 radioimmunoassay and did not account for the observed increases in endothelin-1-like immunoreactivity with increasing concentrations of added fetal calf serum.
HPLC purification of the medium samples was performed before RIA to determine whether the antibody was measuring mature endothelin or its precursor. As shown in Figure 6 , synthetic endothelin-1 eluted at 8.5 min and synthetic big human endothelin-1[1-38) eluted at 12.5 min. Endothelin-2 and endothelin-3 were not tested because the antiserum does not recognize these isoforms of endothelin. The immunoreactive endothelin present in the medium of cultured human endothelial cells CO-eluted with synthetic endothelin-1. No immunoreactivity was detectable at 12.5 min, indicating the absence of measurable big human endothelin-1 . A small peak was detected at 2 min. which represents an unidentified product of endothelial cells that crossreacts with endothelin-1 antiserum. Therefore, endothelin was either released as big endothelin-I and completely converted to the active hormone or was released as the mature hormone in cultured human umbilical vein endothelial cells.
Discussion
The present investigation demonstrates that endothelin-1-like immunoreactivity is present in endothelial cells lining the small-and medium-sized arteries and veins in human placenta. Striking endothelin-1-like immunoreactivity was also seen in the capillaries of placental microvilli, indicating that endothelin is present at the terminal capillaries where nutrient and gas exchange occurs between mother and fetus. Syncytiotrophoblasts, cytotrophoblasts, connective tissue, and vascular smooth muscle cells were consistently negative for endothelin-1-like immunostaining. The distribution of endothelin-1-like immunostaining followed the same pattern as Factor VIII-related antigen, suggesting that all endothelial cells in the human placenta can produce endothelin-like material.
Although the staining reaction was strong in the capillaries of the microvilli, staining in the medium to large arteries and veins was often more focal. This finding is not surprising, considering studies in other organs in which immunostaining for endothelin-1 in the vascular endothelium is focal (26) , as is the distribution of endothelin-1 mRNA (13) . These data suggest that the expression of endothelin in blood vessels is not universal and may be a regulated process. In an earlier report of endothelin immunoreactivity (24) . a similar pattern of staining of placental endothelium was demonstrated. but because of the inability of the antibody to distinguish among endothelin-1, endothelin-2, and endothelin-3 it was not possible to determine which isoform was detected. The antibody used in the present study does not recognize endothelin-2 and endothelin-3 and therefore indicates that the immunohistochemical staining can be attributed to endothelin-1 and/or big endothelin-1. This distinction is important because the endothelin receptor in placenta is Type B, which equally recognizes all three endothelin isoforms (18) . and the potential importance of the various isoforms of endothelin has yet to be determined.
Endothelin-1 is believed to be produced by the cleavage of a large molecule, big human endothelin (27) . The endothelin antiserum used in the present investigation was specific for endothelin-1 and its precursor molecule, big human endothelin . Therefore, the immunohistochemical localization could not differentiate between endothelin-1 and its precursor. There was less than 1% crossreactivity with endothelin-2 and endothelin-3, and no detectable crossreactivity with unrelated peptides (26) .
The nature of the endothelin-1-like immunoreactivity in the human fetoplacental unit was further studied using cultured human umbilical vein endothelial cells. The concentration of endothelin-1-like material released by these cells into tissue culture medium varied directly with incubation time and with the concentration of fetal calf serum. Further characterization of the immunoreactive endothelin by combining HPLC and RIA indicated that all of the immunoreactive material co-eluted with endothelin-1 or with an early peak which remains unidentified. Big human endothelin could not be detected. It is not possible to determine from these experiments whether endothelin-1 was released as the mature form or whether big human endothelin[l-38] was released and quantitatively converted to the mature autacoid. The presence of a second unidentified immunoreactive peak may represent either a metabolite of endothelin-1, a metabolite of big endothelin other than endothelin-1, or another related substance. Additional experiments must be performed to identify the nature of this peak. These findings confirm and extend the findings of a previous report (3) which demonstrated that human umbilical vein endothelial cells secrete endothelin.
The finding that endothelin is produced locally in the human placenta completes the criteria for an autacoid system. We now know that the endothelial cells lining blood vessels and capillaries in the placenta make endothelin in vivo. Endothelin produced in placen- tal capillaries may enhance vascular permeability, as has been previously demonstrated to occur in conscious rats (22) . This evidence, coupled with the previous demonstrations that endothelin consuicts fetoplacental vasculature by acting on specific high-affinity receptor sites, completes the requirements for a tissue-active autacoid system. The presence of this constrictor system in the human fetoplacental circulation raises the important question of its possible physiological role in the regulation of blood flow and vascular permeability in the human fetoplacental vascular bed. Endothelin may play a role in the constriction of umbilical vessels at the time of delivery (7) time (min) Figure 6 . HPLC separation of endothelin-1 and big human endothelin-1. Reversed-phase HPLC was performed to separate authentic standards of endothelin-I and big human endothelin-I, as described in detail in the text. The fractionswere then lyophilized and analyzed for endothelin by RIA. Big human endothelin-1 eluted at 12.5 min and endothelin-1 eluted at 8.5 min. When the medium from cultured human endothelial cells was subjected to HPLC and RIA, two peaks were apparent. One peak co-eluted with authentic endothelin-1 (8.5 min). A second peak at 2 min remains unidentified. There was no detectable big human endothelin-I. Recoveryof authentic endothelin-I standard was 40 2 5% (n = 4). The chromatogram is representative of three studies.
to better delineate the basic mechanisms of endothelin synthesis and conversion in the human placenta, the mechanism of endothelin's long duration of action, and its precise role in the pathogenesis of diseases characterized by reduced fetoplacental blood flow.
